- Conditions
- Cancer
- Interventions
- acupuncture therapy, management of therapy complications, pain therapy
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke
- Interventions
- Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo
- Biological · Drug
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Chattanooga, Tennessee
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Lenalidomide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 44
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
- Conditions
- Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
- Interventions
- AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
- Drug
- Lead sponsor
- Affimed GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 11 more
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 54
- States / cities
- Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more
- Conditions
- Refractory Multiple Myeloma
- Interventions
- pomalidomide, bortezomib, dexamethasone, laboratory biomarker analysis, gene expression analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- VIBEX MTX
- Device
- Lead sponsor
- Antares Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Duncansville, Pennsylvania
- Conditions
- Arthroplasty
- Interventions
- Biomet TMJ Replacement System
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • West Bloomfield, Michigan • Philadelphia, Pennsylvania + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Tanner Foundation for Multiple Sclerosis
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Sclerosis
- Interventions
- Wahls Paleo Plus, Wahls Diet
- Other
- Lead sponsor
- Terry L. Wahls
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Diabetic Foot Ulcers
- Interventions
- AutoloGel
- Device
- Lead sponsor
- Cytomedix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Arcadia, California • Cumming, Georgia
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Camera Based Kinematic Analysis
- Diagnostic Test
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Long QT Syndrome
- Interventions
- LQT-1213, Placebo, Dofetilide 250 μg Cap
- Drug
- Lead sponsor
- Thryv Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Multiple Myeloma, Chronic Lymphocytic Leukemia
- Interventions
- Screening
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Open Angle Glaucoma
- Interventions
- Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
- Procedure · Device
- Lead sponsor
- New World Medical, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- La Crosse, Wisconsin
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- VAY736, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Long Beach, California • San Diego, California
- Conditions
- Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy, Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), Placebo, SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination, SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Rolling Hills Estates, California + 20 more
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- Biomarkers
- Device
- Lead sponsor
- Abbott RDx Cardiometabolic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 18
- States / cities
- Sacramento, California • New Haven, Connecticut • Baltimore, Maryland + 13 more
- Conditions
- Multiple Sclerosis
- Interventions
- Bodyweight training
- Behavioral
- Lead sponsor
- Holy Name Medical Center, Inc.
- Other
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Teaneck, New Jersey
- Conditions
- Stroke, Multiple Sclerosis, Rheumatoid Arthritis
- Interventions
- SystemCHANGE Group Lifestyle counseling, Phone Lifestyle Counseling
- Behavioral
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 9
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Hackensack, New Jersey + 5 more
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more